Meeting
2021 ASCO Annual Meeting
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
Authors
Hui Kong Gan
Austin Health, Heidelberg, VIC, Australia
Hui Kong Gan , Jermaine Coward , Anna Rachelle Austria Mislang , Rasha Cosman , Adnan Nagrial , Xiaoping Jin , Baiyong Li , Zhongmin Maxwell Wang , Kon Yew Kwek , Dennis Xia , Yu Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT04349969
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2630)
DOI
10.1200/JCO.2021.39.15_suppl.2630
Abstract #
2630
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
First Author: Nong Xu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
First Author: Michael J. Overman
Poster
2021 ASCO Annual Meeting
A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.
First Author: Ben Markman